好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cognitive Decline Overtime in Patients with Chronic Pain and Headache: a Systematic Review
Pain
P1 - Poster Session 1 (9:00 AM-5:00 PM)
442
The aim of this systematic review was to assess the risk of cognitive decline among patients with chronic pain and headache overtime. 
Extensive literature focused on the identification of risk and protective factors for cognitive impairment or incident dementia. Some cross-sectional studies reported cognitive decline related to chronic pain but there are few prospective studies assessing this field, with conflicting results. 
The databases used were MEDLINE, PubMed and EMBASE. Eligible studies included cohort studies assessing the risk of cognitive decline overtime in patients with chronic pain and headache, published until September 2021. 

A total of 1301 records were identified and 20 cohort studies were included in this review. Regarding chronic pain, 57.1% (4/7 studies, n = 17368) revealed that chronic pain was a risk factor for cognitive decline, with RR (Risk Ratio) ranging from 1.20 (1.13, 1.27) to 1.80 (1.30-2.49). Headache was also a risk factor for the majority of studies (61.5%, 8/13 studies, n = 315820), with RR ranging from 1.15 (1.05, 1.27) to 2.97 (1.25, 6.61). These studies included participants with similar range of mean age (for chronic pain: 40 to 76.1, for headache: 42.2 to 70) and follow-up ranging from 4 to 27 years (chronic pain) and 5 to 19 years (headache). The lifelong frequency, intensity and interference of pain were not routinely assessed and cognitive evaluation was heterogeneous.

Some studies described cognitive decline involving an older community with chronic pain and headache, and others did not find this association. Other studies analyzed chronic pain and migraine together, although these conditions are different in presentation and pathophysiology. Future publications can clarify some important points related to the fluctuating trajectory of pain and cognitive decline, since it is not clear whether this association is causal or correlational. 
Authors/Disclosures
Karen D. Ferreira, MD, PhD (Montreal Neurological Clinic)
PRESENTER
Dr. Ferreira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Ferreira has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Pfizer.
No disclosure on file